<![CDATA[PSMA-PET/PSA Scans Identifies Residual Disease in Metastatic HPSC ]]>

Data ReadoutNegative

AI Analysis

Summary

The PSMAtrack analysis found that all patients treated with 6 months of systemic therapy for metastatic HSPC retained residual PSMA-avid disease, suggesting limitations in current treatment approaches.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

PSMAtrack analysis identified residual PSMA-avid disease in all patients following 6 months of systemic therapy for metastatic HSPC

Importance:4/10

Sentiment:

-0.30

PSMA-PETmetastatic HSPCresidual diseaseimaging biomarkerPSMAtrack

Read the original article

Published by Cancer Network on June 3, 2026 5:00 PM

Read Original